Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Stem Cell Therapy in Patients With Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between the ages of 3 and 12 years.~* DSM-IV diagnosis of Autistic Disorder.~* Total score of CARS ≥ 30.~* Parents or legal guardian willing to sign the ICF.~Exclusion Criteria:~* Any history of hypersensitivity to serum products, or other known drug and food allergy.~* History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's.~* History of Epileptic seizure activity in the past 6 months.~* Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.~* The global autism ratings are assessed as being absent, minimal or mild.~* Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive dyskinesia.~* Subjects who have displayed significant self-injurious behavior (children who have caused visible harm to themselves).~* HIV+~* Acute and chronic hepatitis.~* Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.~* Severe pulmonary and hematological disease, malignancy or hypo-immunity.~* Currently undertaking other treatment that may affect the safety/efficacy of stem cells.~* Enrollment in other trials in the last 3 months.~* Other criteria the investigator consider improper for inclusion.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Rehabilitation plus hCB-MNCs treatment (Type: EXPERIMENTAL): Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
- Rehabilitation plus hCB-MNCs and hUC-MSCs therapy (Type: EXPERIMENTAL): Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).